The development of innovative cancer therapies has led to unprecedented improvement in survival outcomes and diverse treatment-related toxicities, including those with cardiovascular in nature. Aging population further increase the number of patients being treated for cancer, especially those with comorbidities. As existing and developing cardiovascular disease poses some the greatest risk of morbidity and mortality in patients with cancer.
Addressing the needs of complex cardiovascular patients has become increasingly important, which resulted in important for intersecting disciplines: cardio-oncology. Over the past decade, there has been a remarkable improvement of cardio-oncology clinics and service lines. This development, however, has occurred in a vacuum practice guidelines and training standards, although these are being actively pursued. In the document the board’s perspective, the authors describe the scope of practice in oncology and cardio-training requirements proposed, and the core competencies required. This document also serves as a road map to confirm cardio-oncology as a subspecialty of medicine.
The use of biomarkers to guide the selection of patients and therapies have gained a lot of attention to improving the scope and complexity of the selection of targeted therapy and immunotherapy. Clinical trials provide the basis for the discovery of biomarkers, which can then help in the development of new drugs. For that, a sample of cancer patients, including DNA, RNA, proteins, and metabolome isolated from cancerous tissue and blood or urine, is analyzed in a variety of ways to identify relevant biomarkers. In conjunction with the nucleotide-based, high-throughput, next-generation sequencing techniques, therapy-guided tests rely immunohistochemistry biomarker-based proteins play an important role in cancer treatment. In this review, we discuss the current knowledge of DNA and protein biomarkers for cancer immunotherapy.
both the primary and recurrence of cancer in patients after resection of colorectal cancer: An analysis of the integrated test with the Japan Clinical Oncology Group: JCOG1702A
Background: Improved early detection and treatment have resulted in an increase in the number of long-term victims of colorectal cancer (CRC). For the victims, a second primary cancers and recurrences are important issues; However, the evidence for the study of appropriate control strategies limited.This remnants aims to determine the frequency and timing of a second primary cancer in patients after surgery to explore the appropriate control strategies using an integrated analysis of three large-scale randomized controlled trials in Japan.
Methods: The eligibility criteria of the three trials included histologically confirmed CRC and receive operations. Time, location and frequency of second primary cancers and recurrences investigated. risk factors associated with a second primary cancer were also examined. standard incidence ratio (SIR) of a second primary cancer in comparison to the national database of the Cancer Registry of Japan is expected.
Results: A total of 2824 patients were included in this study. The cumulative incidence of second primary cancers increased from time to time. SIR of each second primary cancer was 1.07 (95% CI: 0.94 to 1.21). SIR for second primary cancers intestine was 1.09 (95% CI: 0.79 to 1.47). The cumulative incidence of recurrence nearly reached a plateau at 3 years.
Conclusions: A strategy for the general supervision of the general population can be applied even to patients curatively resected CRC, as a second primary cancer risk is nearly the same as the general population.
Adherence to Oral Anticancer Therapeutics in Gynecologic Oncology Population
Introduction: To get a better understanding of gynecologic oncology patient compliance with oral anticancer agents through both cross-sectional survey of compliance and qualitative interviews with patients and physicians about their experiences with the drug.
Methods: Participants were eligible completing the survey for this cross-sectional study that included an assessment of compliance, distress, quality of life, and health literacy. Each woman takes oral anticancer agent for gynecological malignancies in a tertiary academic medical center for 30 days or more to qualify. semi-structured qualitative interviews (n = 14) was then performed to explore the experience with oral anticancer agent. We also perform qualitative group interviews with doctors and nurse practitioners.
Results: One hundred women taking oral anticancer agent listed. Fifty-four percent reported perfect adherence to their treatment, 21% reported a vague compliance (indicating at least one nonadherent behavior in the previous 7 days), and 25% reported non-compliance (indicating more than one behavior nonadherent within 7 days in advance). Qualitative analysis identified five main themes: the ease of use compared to traditional therapies; drugs self-administered mental burden; the perceived importance of the drug; management of side effects; and the desire for physician communication consistent. common misperception stated in an interview health care professionals including the high adherence to oral medication and a belief that the cost is the biggest barrier to compliance.
 (3-36)-Gly (Human) - Antibody) Peptide YY (PYY) (3-36)-Gly (Human) - Antibody |
|
H-059-08 |
PHOENIX PEPTIDE |
100 μl |
EUR 469.8 |
 (3-19) (Human) - Antibody) [Cys0]-Peptide YY (PYY) (3-19) (Human) - Antibody |
|
H-059-16 |
PHOENIX PEPTIDE |
100 μl |
EUR 469.8 |
 (Human) - Antibody) Gastrin Releasing Peptide (GRP) (Human) - Antibody |
|
H-027-07 |
PHOENIX PEPTIDE |
50 μl |
EUR 238.68 |
 (3-19) (Human) - Antibody) [Cys20]-Peptide YY (PYY) (3-19) (Human) - Antibody |
|
H-059-17 |
PHOENIX PEPTIDE |
100 μl |
EUR 469.8 |
 (Human) - Purified IgG Antibody) Peptide YY (PYY) (Human) - Purified IgG Antibody |
|
G-059-01 |
PHOENIX PEPTIDE |
400 μg |
EUR 438.48 |
 (Human) - Antibody) Stresscopin Related Peptide (SRP) (Human) - Antibody |
|
H-019-27 |
PHOENIX PEPTIDE |
50 μl |
EUR 604.8 |
 (Human) - EIA Kit) Peptide YY (PYY) (Human) - EIA Kit |
|
EK-059-01 |
PHOENIX PEPTIDE |
96 wells |
EUR 617.76 |
 (Human) - RIA Kit) Peptide YY (PYY) (Human) - RIA Kit |
|
RK-059-01 |
PHOENIX PEPTIDE |
125 tubes |
EUR 814.32 |
 (Human)) Galanin-Like Peptide (GALP) (Human) |
|
026-51 |
PHOENIX PEPTIDE |
100 μg |
EUR 230.04 |
 (36-60) (Human) - Antibody) Galanin-Like Peptide (GALP) (36-60) (Human) - Antibody |
|
H-026-55 |
PHOENIX PEPTIDE |
50 μl |
EUR 604.8 |
 (Human)) T3 Peptide / Tumstatin (69-88) (Human) |
|
016-50 |
PHOENIX PEPTIDE |
100 μg |
EUR 255.96 |
 (Human)) T7 Peptide / Tumstatin (74-98) (Human) |
|
016-51 |
PHOENIX PEPTIDE |
100 μg |
EUR 255.96 |
 Anti-Angiogenic Peptide Library |
|
L-008A |
PHOENIX PEPTIDE |
88 peptides |
EUR 6067.44 |
 (Human)) Gastrin Releasing Peptide (GRP) (Human) |
|
027-07 |
PHOENIX PEPTIDE |
200 μg |
EUR 119.88 |
 (Human) - Antibody) Prolactin-Releasing Peptide-31 (PrRP-31) (Human) - Antibody |
|
H-008-50 |
PHOENIX PEPTIDE |
50 μl |
EUR 604.8 |
 (3-36) (Human) - Purified IgG Antibody) Peptide YY (PYY) (3-36) (Human) - Purified IgG Antibody |
|
G-059-02 |
PHOENIX PEPTIDE |
200 μg |
EUR 604.8 |
 / Peptide Histidine Isoleucine (PHI) (Human)) Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) |
|
064-07 |
PHOENIX PEPTIDE |
200 μg |
EUR 114.48 |
 / Peptide Histidine Isoleucine (PHI) (Human) - Purified IgG Antibody) Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - Purified IgG Antibody |
|
G-064-07 |
PHOENIX PEPTIDE |
400 μg |
EUR 438.48 |
 (1-36)-Gly (Human)) Peptide YY (PYY) (1-36)-Gly (Human) |
|
059-07 |
PHOENIX PEPTIDE |
100 μg |
EUR 295.92 |
 (3-36)-Gly (Human)) Peptide YY (PYY) (3-36)-Gly (Human) |
|
059-08 |
PHOENIX PEPTIDE |
100 μg |
EUR 282.96 |
 (2-36)-Gly (Human)) Peptide YY (PYY) (2-36)-Gly (Human) |
|
059-11 |
PHOENIX PEPTIDE |
100 μg |
EUR 267.84 |
 (4-36)-Gly (Human)) Peptide YY (PYY) (4-36)-Gly (Human) |
|
059-12 |
PHOENIX PEPTIDE |
100 μg |
EUR 267.84 |
 (Human)) Stresscopin Related Peptide (SRP) (Human) |
|
019-27 |
PHOENIX PEPTIDE |
100 μg |
EUR 214.92 |
 (Human)) SHAAG Peptide / Chemokine (46-63) (Human) |
|
072-32 |
PHOENIX PEPTIDE |
100 μg |
EUR 160.92 |
 (Human)) Defensin I / Human Neutrophil Peptide-1 (HNP-1) (Human) |
|
072-17 |
PHOENIX PEPTIDE |
100 μg |
EUR 370.44 |
 (Human) - Antibody) RFamide-Related Peptide 3 (RFRP-3) (Human) - Antibody |
|
H-048-46 |
PHOENIX PEPTIDE |
100 μl |
EUR 604.8 |
 (Human)) Fractalkine Chemokine Domain peptide (41-52) (Human) |
|
026-82 |
PHOENIX PEPTIDE |
200 μg |
EUR 160.92 |
 (Human)) Fractalkine Chemokine Domain peptide (53-60) (Human) |
|
026-83 |
PHOENIX PEPTIDE |
200 μg |
EUR 135 |
 (Human)) Fractalkine Chemokine Domain peptide (60-71) (Human) |
|
026-84 |
PHOENIX PEPTIDE |
200 μg |
EUR 160.92 |
) C28 optimized peptide 15 Dimer (Human) |
|
073-86 |
PHOENIX PEPTIDE |
100 μg |
EUR 420.12 |
 (Human)) Osteoblast Activating Peptide (OBAP) (Human) |
|
055-52 |
PHOENIX PEPTIDE |
100 μg |
EUR 199.8 |
 Human Proteome Signature Peptide Library |
|
L-010 |
PHOENIX PEPTIDE |
98 peptides |
EUR 7804.08 |
 - Antibody) Urotensin II Related Peptide (Human, Rat, Mouse) - Antibody |
|
H-071-17 |
PHOENIX PEPTIDE |
50 μl |
EUR 604.8 |
 (Human)) Nesfatin-1-Like Peptide (NLP) (Human) |
|
009-83 |
PHOENIX PEPTIDE |
100 μg |
EUR 469.8 |
 (Human)) APP 17mer peptide / APP770 (204-220) (Human) |
|
018-74 |
PHOENIX PEPTIDE |
100 μg |
EUR 135 |
) C28 optimized peptide 15 Monomer (Human) |
|
073-84 |
PHOENIX PEPTIDE |
100 μg |
EUR 258.12 |
 (3-36) (Human) - EIA Kit) Peptide YY (PYY) (3-36) (Human) - EIA Kit |
|
EK-059-02 |
PHOENIX PEPTIDE |
96 wells |
EUR 617.76 |
 (3-36) (Human) - RIA Kit) Peptide YY (PYY) (3-36) (Human) - RIA Kit |
|
RK-059-02 |
PHOENIX PEPTIDE |
125 tubes |
EUR 814.32 |
 (Human) - Purified IgG Antibody) Galanin-Like Peptide (GALP) (Human) - Purified IgG Antibody |
|
G-026-51 |
PHOENIX PEPTIDE |
200 μg |
EUR 604.8 |
 (Human) - I-125 Labeled) Peptide YY (PYY) (Human) - I-125 Labeled |
|
T-059-01 |
PHOENIX PEPTIDE |
10 μCi |
EUR 1145.88 |
) SHLP1 / Small Humanin-Like Peptide 1 (Human) |
|
018-75 |
PHOENIX PEPTIDE |
100 μg |
EUR 263.52 |
) SHLP2 / Small Humanin-Like Peptide 2 (Human) |
|
018-76 |
PHOENIX PEPTIDE |
100 μg |
EUR 263.52 |
) SHLP3 / Small Humanin-Like Peptide 3 (Human) |
|
018-77 |
PHOENIX PEPTIDE |
100 μg |
EUR 422.28 |
) SHLP4 / Small Humanin-Like Peptide 4 (Human) |
|
018-78 |
PHOENIX PEPTIDE |
100 μg |
EUR 289.44 |
) SHLP5 / Small Humanin-Like Peptide 5 (Human) |
|
018-79 |
PHOENIX PEPTIDE |
100 μg |
EUR 316.44 |
) SHLP6 / Small Humanin-Like Peptide 6 (Human) |
|
018-80 |
PHOENIX PEPTIDE |
100 μg |
EUR 250.56 |
 (Human) - Purified IgG Antibody) Gastrin Releasing Peptide (GRP) (Human) - Purified IgG Antibody |
|
G-027-07 |
PHOENIX PEPTIDE |
400 μg |
EUR 438.48 |
 (36-60) (Human)) Galanin-Like Peptide (GALP) (36-60) (Human) |
|
026-55 |
PHOENIX PEPTIDE |
200 μg |
EUR 177.12 |
 / Peptide Histidine Isoleucine (PHI) (Human) - RIA Kit) Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - RIA Kit |
|
RK-064-07 |
PHOENIX PEPTIDE |
125 tubes |
EUR 932.04 |
optimized peptide 10 (Human)) FGF23 (188-199 )optimized peptide 10 (Human) |
|
073-88 |
PHOENIX PEPTIDE |
100 μg |
EUR 258.12 |
 (83-132) amide (Human) - Antibody) Agouti-Related Peptide (AgRP) (83-132) amide (Human) - Antibody |
|
H-003-53 |
PHOENIX PEPTIDE |
50 μl |
EUR 469.8 |
 (Human)) Prolactin-Releasing Peptide-31 (PrRP-31) (Human) |
|
008-50 |
PHOENIX PEPTIDE |
200 μg |
EUR 199.8 |
 (Human)) Prolactin-Releasing Peptide-20 (PrRP-20) (Human) |
|
008-51 |
PHOENIX PEPTIDE |
200 μg |
EUR 199.8 |
 (3-36) (Human) - FAM Labeled) Peptide YY (PYY) (3-36) (Human) - FAM Labeled |
|
FG-059-02A |
PHOENIX PEPTIDE |
1 nmol |
EUR 336.96 |
 (Human) - Purified IgG Antibody) Stresscopin Related Peptide (SRP) (Human) - Purified IgG Antibody |
|
G-019-27 |
PHOENIX PEPTIDE |
200 μg |
EUR 604.8 |
 (25-51) (Human)) Agouti-Related Peptide (AgRP) (25-51) (Human) |
|
003-51 |
PHOENIX PEPTIDE |
200 μg |
EUR 129.6 |
 (54-82) (Human)) Agouti-Related Peptide (AgRP) (54-82) (Human) |
|
003-52 |
PHOENIX PEPTIDE |
200 μg |
EUR 129.6 |
 (25-82) (Human)) Agouti-Related Peptide (AgRP) (25-82) (Human) |
|
003-74 |
PHOENIX PEPTIDE |
100 μg |
EUR 497.88 |
 (18-27) (Human)) Gastrin Releasing Peptide (GRP) (18-27) (Human) |
|
027-41 |
PHOENIX PEPTIDE |
200 μg |
EUR 160.92 |
 (1-16) (Human)) Gastrin Releasing Peptide (GRP) (1-16) (Human) |
|
027-08 |
PHOENIX PEPTIDE |
1 mg |
EUR 177.12 |
 (1-17) (Human)) Gastrin Releasing Peptide (GRP) (1-17) (Human) |
|
027-42 |
PHOENIX PEPTIDE |
200 μg |
EUR 189 |
) Seminal Plasma Inhibin-Like Peptide (Human) |
|
034-03 |
PHOENIX PEPTIDE |
200 μg |
EUR 194.4 |
 / Peptide Histidine Isoleucine (PHI) (Human) - FAM Labeled) Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - FAM Labeled |
|
FG-064-07A |
PHOENIX PEPTIDE |
1 nmol |
EUR 336.96 |
 (Human) - RIA Kit) Galanin-Like Peptide (GALP) (Human) - RIA Kit |
|
RK-026-51 |
PHOENIX PEPTIDE |
125 tubes |
EUR 932.04 |
 (3-36) (Human) - Biotin Labeled) Peptide YY (PYY) (3-36) (Human) - Biotin Labeled |
|
B-059-02 |
PHOENIX PEPTIDE |
10 μg |
EUR 405 |
 (80-97) (Human) - Antibody) [Tyr0]-pro-Gastrin Releasing Peptide (GRP) (80-97) (Human) - Antibody |
|
H-027-36 |
PHOENIX PEPTIDE |
100 μl |
EUR 370.44 |
 (36-60) (Human) - Purified IgG Antibody) Galanin-Like Peptide (GALP) (36-60) (Human) - Purified IgG Antibody |
|
G-026-55 |
PHOENIX PEPTIDE |
200 μg |
EUR 604.8 |
 (Human) - Purified IgG Antibody) Prolactin-Releasing Peptide-31 (PrRP-31) (Human) - Purified IgG Antibody |
|
G-008-50 |
PHOENIX PEPTIDE |
400 μg |
EUR 604.8 |
 (Human)) RFamide-Related Peptide 1 (RFRP-1) (Human) |
|
048-42 |
PHOENIX PEPTIDE |
500 μg |
EUR 177.12 |
 (Human)) RFamide-Related Peptide 2 (RFRP-2) (Human) |
|
048-44 |
PHOENIX PEPTIDE |
500 μg |
EUR 177.12 |
 (Human)) RFamide-Related Peptide 3 (RFRP-3) (Human) |
|
048-46 |
PHOENIX PEPTIDE |
500 μg |
EUR 177.12 |
 (Human) - EIA Kit) Gastrin Releasing Peptide (GRP) (Human) - EIA Kit |
|
EK-027-07 |
PHOENIX PEPTIDE |
96 wells |
EUR 603.72 |
 (Human) - RIA Kit) Gastrin Releasing Peptide (GRP) (Human) - RIA Kit |
|
RK-027-07 |
PHOENIX PEPTIDE |
125 tubes |
EUR 932.04 |
) Urotensin II Related Peptide (Human, Rat, Mouse) |
|
071-17 |
PHOENIX PEPTIDE |
200 μg |
EUR 129.6 |
 / Peptide Histidine Isoleucine (PHI) (Human) - I-125 Labeled) Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - I-125 Labeled |
|
T-064-07 |
PHOENIX PEPTIDE |
10 μCi |
EUR 1145.88 |
 (Human) - FAM Labeled) T3 Peptide / Tumstatin (69-88) (Human) - FAM Labeled |
|
FG-016-50A |
PHOENIX PEPTIDE |
1 nmol |
EUR 469.8 |
 (Human) - FAM Labeled) T7 Peptide / Tumstatin (74-98) (Human) - FAM Labeled |
|
FG-016-51A |
PHOENIX PEPTIDE |
1 nmol |
EUR 469.8 |
 (Human) - FAM Labeled) Galanin-Like Peptide (GALP) (Human) - FAM Labeled |
|
FG-026-51A |
PHOENIX PEPTIDE |
1 nmol |
EUR 604.8 |
 (Human) - RIA Kit) Stresscopin Related Peptide (SRP) (Human) - RIA Kit |
|
RK-019-27 |
PHOENIX PEPTIDE |
125 tubes |
EUR 1341.36 |
 (3-36) (Human) - I-125 Labeled) Peptide YY (PYY) (3-36) (Human) - I-125 Labeled |
|
T-059-02 |
PHOENIX PEPTIDE |
10 μCi |
EUR 1145.88 |
 (3-36) (Human) - Rhodamine Labeled) Peptide YY (PYY) (3-36) (Human) - Rhodamine Labeled |
|
FR-059-02 |
PHOENIX PEPTIDE |
1 nmol |
EUR 405 |
 (25-51) (Human)) [Tyr0]-Agouti-Related Peptide (AgRP) (25-51) (Human) |
|
003-72 |
PHOENIX PEPTIDE |
100 μg |
EUR 416.88 |
 (54-82) (Human)) [Tyr0]-Agouti-Related Peptide (AgRP) (54-82) (Human) |
|
003-73 |
PHOENIX PEPTIDE |
100 μg |
EUR 416.88 |
 (Human)) Gastrin Releasing Peptide-Gly (GRP-Gly) (Human) |
|
027-37 |
PHOENIX PEPTIDE |
100 μg |
EUR 160.92 |
 (3-36) (Human) - MagBead (Magnetic Bead Linked Antibody)) Peptide YY (PYY) (3-36) (Human) - MagBead (Magnetic Bead Linked Antibody) |
|
MB-059-02 |
PHOENIX PEPTIDE |
1 ml |
EUR 842.4 |
 R / I5 Chimeric Peptide (Human)) R3 (BDelta23-27) R / I5 Chimeric Peptide (Human) |
|
035-66 |
PHOENIX PEPTIDE |
100 μg |
EUR 604.8 |
 (Human) - RIA Kit) Nesfatin-1-Like Peptide(NLP) (Human) - RIA Kit |
|
RK-009-83 |
PHOENIX PEPTIDE |
125 tubes |
EUR 980.64 |
 (56-92) amide (Human) - Antibody) prepro-RFamide Related Peptide (RFRP) (56-92) amide (Human) - Antibody |
|
H-048-54 |
PHOENIX PEPTIDE |
100 μl |
EUR 604.8 |
 (115-131) amide (Human) - Antibody) prepro-RFamide Related Peptide (RFRP) (115-131) amide (Human) - Antibody |
|
H-048-55 |
PHOENIX PEPTIDE |
50 μl |
EUR 604.8 |
 (42-98) (Human)) pro-Gastrin Releasing Peptide (GRP) (42-98) (Human) |
|
027-34 |
PHOENIX PEPTIDE |
100 μg |
EUR 355.32 |
 (47-68) (Human)) pro-Gastrin Releasing Peptide (GRP) (47-68) (Human) |
|
027-35 |
PHOENIX PEPTIDE |
100 μg |
EUR 160.92 |
 (Human) - FAM Labeled) SHAAG Peptide / Chemokine (46-63) (Human) - FAM Labeled |
|
FG-072-32A |
PHOENIX PEPTIDE |
1 nmol |
EUR 267.84 |
 (Human) - Cy3 Labeled) SHAAG Peptide / Chemokine (46-63) (Human) - Cy3 Labeled |
|
FC3-072-32 |
PHOENIX PEPTIDE |
1 nmol |
EUR 587.52 |
 (Human) - Cy5 Labeled) SHAAG Peptide / Chemokine (46-63) (Human) - Cy5 Labeled |
|
FC5-072-32 |
PHOENIX PEPTIDE |
1 nmol |
EUR 587.52 |
 peptide (Human, Porcine)) 7B2 Carboxyl-terminal (CT) peptide (Human, Porcine) |
|
004-32 |
PHOENIX PEPTIDE |
100 μg |
EUR 160.92 |
 (Human) - EIA Kit) Osteoblast Activating Peptide (OBAP) (Human) - EIA Kit |
|
EK-055-52 |
PHOENIX PEPTIDE |
96 wells |
EUR 660.96 |
 (Human) - RIA Kit) Osteoblast Activating Peptide (OBAP) (Human) - RIA Kit |
|
RK-055-52 |
PHOENIX PEPTIDE |
125 tubes |
EUR 980.64 |
 (71-132), Form C amide (Human) - Antibody) Agouti-Related Peptide (AgRP) (71-132), Form C amide (Human) - Antibody |
|
H-003-55 |
PHOENIX PEPTIDE |
50 μl |
EUR 604.8 |
 (87-116) (Human)) prepro-Galanin-Like Peptide (GALP) (87-116) (Human) |
|
026-54 |
PHOENIX PEPTIDE |
200 μg |
EUR 230.04 |
 (Human) - FAM Labeled) Stresscopin Related Peptide (SRP) (Human) - FAM Labeled |
|
FG-019-27A |
PHOENIX PEPTIDE |
1 nmol |
EUR 537.84 |
 (3-36) (Human) - Fluorescent EIA Kit) Peptide YY (PYY) (3-36) (Human) - Fluorescent EIA Kit |
|
FEK-059-02 |
PHOENIX PEPTIDE |
96 wells |
EUR 660.96 |
6,(15N)-15,22]-Peptide YY (PYY) (3-36) (Human)) [Leu(13C)6,(15N)-15,22]-Peptide YY (PYY) (3-36) (Human) |
|
SIL-059-02 |
PHOENIX PEPTIDE |
20 μg |
EUR 1186.92 |
 (83-132) amide (Human)) Agouti-Related Peptide (AgRP) (83-132) amide (Human) |
|
003-53 |
PHOENIX PEPTIDE |
100 μg |
EUR 316.44 |
 (14-27) (Human, Porcine)) Gastrin Releasing Peptide (GRP) (14-27) (Human, Porcine) |
|
027-16 |
PHOENIX PEPTIDE |
500 μg |
EUR 108 |
 - Purified IgG Antibody) Urotensin II Related Peptide (Human, Rat, Mouse) - Purified IgG Antibody |
|
G-071-17 |
PHOENIX PEPTIDE |
200 μg |
EUR 604.8 |
 (Human)) [Tyr0]-RFamide-Related Peptide 1 (RFRP-1) (Human) |
|
048-43 |
PHOENIX PEPTIDE |
200 μg |
EUR 177.12 |
 (Human)) [Tyr0]-RFamide-Related Peptide 2 (RFRP-2) (Human) |
|
048-45 |
PHOENIX PEPTIDE |
200 μg |
EUR 177.12 |
 (Human)) [Tyr0]-RFamide-Related Peptide 3 (RFRP-3) (Human) |
|
048-47 |
PHOENIX PEPTIDE |
200 μg |
EUR 177.12 |
 (Human) - Rhodamine Labeled) Galanin-Like Peptide (GALP) (Human) - Rhodamine Labeled |
|
FR-026-51 |
PHOENIX PEPTIDE |
1 nmol |
EUR 604.8 |
 (140-173) (Human)) Parathyroid Hormone-Like Peptide (PLP) (140-173) (Human) |
|
056-17 |
PHOENIX PEPTIDE |
200 μg |
EUR 129.6 |
 (Human) - Biotin Labeled) SHAAG Peptide / Chemokine (46-63) (Human) - Biotin Labeled |
|
B-072-32 |
PHOENIX PEPTIDE |
10 μg |
EUR 267.84 |
 (243-261) / C-terminal PSA peptide (Human)) Prostate Specific Antigen (PSA) (243-261) / C-terminal PSA peptide (Human) |
|
034-45 |
PHOENIX PEPTIDE |
100 μg |
EUR 199.8 |
 (Human) - EIA Kit) Prolactin-Releasing Peptide-31 (PrRP-31) (Human) - EIA Kit |
|
EK-008-50 |
PHOENIX PEPTIDE |
96 wells |
EUR 603.72 |
 (Human) - RIA Kit) Prolactin-Releasing Peptide-31 (PrRP-31) (Human) - RIA Kit |
|
RK-008-50 |
PHOENIX PEPTIDE |
125 tubes |
EUR 932.04 |
 (Human) - I-125 Labeled) Galanin-Like Peptide (GALP) (Human) - I-125 Labeled |
|
T-026-51 |
PHOENIX PEPTIDE |
10 μCi |
EUR 1145.88 |
Conclusion: Nearly half of the patients surveyed reported vague or non-compliance with their oral anticancer agent. Qualitative interviews identified several important themes, many of which are not recognized by physicians and nurse practitioners. These findings highlight the need for the patient and health care professional interventions to improve patient adherence.
